国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (8): 703-705.doi: 10.3760/cma.j.issn.1673422X.2016.09.016

• 综述 • 上一篇    下一篇

非小细胞肺癌中HGF/cMet信号通路与EGFRTKI获得性耐药的关系

聂琳, 徐玉清   

  1. 150086 哈尔滨医科大学附属第二医院肿瘤内科
  • 出版日期:2016-09-08 发布日期:2016-08-04
  • 通讯作者: 徐玉清，Email: xyuqing@yahoo.com E-mail:xyuqing@yahoo.com

Relationship between abnormal activation of HGF/cMet signaling pathway and EGFRTKI acquired resistance in nonsmall cell lung cancer

Nie Lin, Xu Yuqing   

  1. Department of Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
  • Online:2016-09-08 Published:2016-08-04
  • Contact: Xu Yuqing E-mail:xyuqing@yahoo.com

PDF

1356

摘要： 表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI)为首的靶向药物在晚期非小细胞肺癌患者治疗中取得巨大进展。然而，获得性耐药的出现是其不可避免的结果。肝细胞生长因子（HGF）/cMet信号通路参与多种肿瘤细胞的形成、迁徙、血管生成等重要细胞进程。该信号通路的异常激活在EGFRTKI获得性耐药中发挥了重要作用。实验表明，HGF/cMet信号通路抑制剂可使部分EGFRTKI获得性耐药患者临床获益。

关键词: 原癌基因蛋白质cmet, 肝细胞生长因子, 癌, 非小细胞肺

Abstract: Targeted therapy such as the epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) has made huge progress in treatment of nonsmall cell lung cancer (NSCLC). However, the emergence of acquired drug resistance is an inevitable result of the targeted therapy. The hepatocyte growth factor/cmesenchymalepithelial transition factor (HGF/cMet) signaling pathway participates in cell formation, migration, angiogenesis and other important cellular processes of multiple tumors. The abnormal activation of this signaling pathway plays the pivotal role in the acquired resistance to EGFRTKI. Recently, some clinic trials prove that HGF/cMet inhibitors can make clinical benefit of some NSCLC patients with acquired drug resistance of EGFRTKI.

Key words: Protooncogene protein cmet, Hepatocyte growth factor, Carcinoma, nonsmallcell lung